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Background and Objective. Diagnosis and management of primary immune thrombocytopenia (ITP) have changed dramatically
in the last decade. The aim of the study was to obtain information about the opinion of the Spanish ITP Group (GEPTI) members
regarding the best clinical practices for diagnosis and management of adult patients with ITP. Materials and Methods. A two-
round Delphi method was carried out by sending to 129 experts a 90-item questionnaire developed by 11 specialists, with a
4-point Likert scale (“never,” “sometimes,” “frequently,” and “always”) for the assessment of responses. Results. Forty out of
the 129 experts participated in the survey (participation rate 30.2%) and 39 completed the questionnaire (response rate 97.5%).
Salient consensus points included the following: the need to indicate workup studies from a sustained platelet count < 100 x
109/L in the absence of a clear etiology; bone marrow aspiration in elderly patients with suspected ITP; beginning treatment
in asymptomatic patients with a platelet count < 20 x 109/L; not exceeding 6-7 weeks of corticosteroid therapy; switching from
corticosteroids to one thrombopoietin receptor agonist (TRA); switching to other TRA or other options as combinations of them
with immunosuppressive drugs in case of failure; how to reduce tapering TRA; treating patients with symptomatic persistent ITP
and platelet count > 20 x 109/L; and considering mucosal or severe bleeding as a basic criterion for hospital admission. Conclusions.
The present consensus document provides a reference framework for the management of patients with ITP in clinical prac-
tice.
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1. Introduction
Immune thrombocytopenia (ITP) is an acquired autoim-
mune disorder defined by isolated thrombocytopenia in the
absence of other conditions associated with thrombocytope-
nia. Given the variability of ITP in clinical presentation,
symptoms, and clinical course, the diagnosis relies on the
exclusion of an alternative etiology for thrombocytopenia
[1–4]. Regarding the pathogenesis, thrombocytopenia seems
to be the result of dysregulation of the immune response,
including the presence of antiplatelet antibodies, platelet
destruction mediated by T-cells and the reticuloendothelial
system, and impaired megakaryocyte function. The involve-
ment of these pathogenic mechanisms may vary in the
individual patient [2, 5–7].
Recommendations on standardization of terminology,
definitions, and criteria of response of ITP were published
in 2009 [8]. Different consensus documents for the diagnosis
and treatment of ITP published subsequently [9–12] have
been of remarkable value to reduce heterogeneity in the clas-
sification of patients and to improve the design and interpre-
tation of results of clinical trials. Also, the reduced relevance
of the platelet count in the occurrence of specific bleeding
symptoms has contributed to improve the management of
the disease by reducing adverse effects related to inadequate
treatments [13, 14]. The development of drugs that can delay
or even avoid the need of performing a splenectomy, such as
thrombopoietin receptor agonists (TRAs), romiplostim, and
eltrombopag [15–18], has been crucial to decrease morbidity,
historically related to infections and bleeding.
ITP is a heterogeneous disease whose evolution and
response to treatment is unpredictable at diagnosis [19]. The
availability of new therapeutic options has raised new ques-
tions in the current approach to ITP management, intro-
ducing considerable variability in clinical practice. A recent
multicenter study carried out in 15 Spanish hospitals showed
remarkable differences in diagnosis and treatment of patients
with ITP [20]. Thus, unanswered questions remain, such as
how to identify patients who need treatment since many
are asymptomatic despite thrombocytopenia or, in case of
need for treatment, how to select the most appropriate
option. In most cases an individualized approach is required
considering platelet count, presence of bleeding, lifestyle,
and other patient characteristics as well as potential adverse
effects of treatment.
In order to clarify uncertainties about patient manage-
ment and to select themost adequate treatment, a study using
the Delphi method has been carried out on different aspects
associated with the diagnosis of ITP, first- and second-line
treatments, followup, and therapeutic approach in special
settings. The objective of this project was to assess the level
of agreement among expert hematologists regarding the
best clinical practices for the diagnosis and management of
patients with ITP.
2. Materials and Methods
In order to establish the present recommendations on the
management of ITP patients in daily clinical practice, a
consultation was made to a group of hematologists experts
in the care of patients with ITP, members of the Spanish ITP
Group (GEPTI) of the Spanish Society of Hematology and
Hemotherapy (SEHH) routinely manage. Different aspects
of the disease that in the hematologists’ opinion should be
considered in the study and treatment of patients with ITP
were considered. A modified Delphi method was used to
reach consensus. The original Delphi method involves three
or more rounds, whereas the modified technique is limited to
two rounds to avoid losses of acceptable response rates due to
prolonged duration of the process and the negative influence
on the interest of the panelists.
At the beginning of the project, a Scientific Commit-
tee composed of 11 specialists with proven experience and
interest in the study of ITP was established. The scientific
committee was responsible for the development of a 90-
item questionnaire on ITP. Questions were grouped into
eight sections: diagnosis (4 items), first-line treatment (11
items), second-line treatment (12 items), persistent ITP and
refractory patients (16 items), followup (12 items), pregnant
patients (12 items), safety and management of emergency
and surgery (14 items), and secondary ITP (3 items). Each
question was formulated so that it could be answered using
a 4-point Likert scale, 1 = “never”, 2 = “sometimes”, 3 =
“frequently”, and 4 = “always” according to the participant’s
opinion regarding what should be performed in clinical
practice.
The questionnaire was sent to a total of 129 hematolo-
gists who were members of the GEPTI. At the end of the
first round, participants’ responses were collected and sent
to the members of the Scientific Committee for analysis.
Subsequently, a meeting was organized with the members
of the Scientific Committee to share and discuss the results
obtained. In thismeeting and based on the consensus reached
in the first round, it was decided that the answers obtained
were sufficiently adequate to be included in the final study
questionnaire.
Only fully completed questionnaires were considered for
analysis. For each item, the median value of the four possible
responses in the 4-point Likert scale was calculated. Consid-
ering median values, questions with a higher proportion of
high frequency responses (“frequently” and “always”) were
grouped as opposed to those of low frequency (“sometimes”
and “never”) to facilitate the analysis. Consensus was estab-
lished in favor of the recommendation when the sum of
the responses “frequently” (Likert score 3) and “always”
(Likert score 4) was equal to or greater than two thirds
(66.6%) of the total responses obtained for that item. By
contrast, consensus against the recommendation was reached
when the sum of responses “sometimes” (Likert score 2) and
“never” (Likert score 1) was equal to or greater than 66.6%
of the total responses obtained for that item. When none of
these previous assumptions were met, consensus neither in
favor nor against the statement was reached.
3. Results
3.1. Characteristics of Participants. Of the 129 experts to
whom the questionnaire was sent, 40 participated in the
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reshold: consensus in favor
(Always / Frequently > 66%)
Do you consider appropriate to initiate the study of 
without any other clear cause that may justify it?
Do you consider appropriate to indicate bone marrow 
aspiration in all patients with suspected ITP?
Do you consider appropriate to indicate bone marrow aspiration 
in case of elderly patients with suspected ITP?
Do you consider appropriate to indicate a study of
Helicobacter pylori aer diagnosis or suspicion of ITP?
reshold: consensus against 
(Never / Sometimes > 66%)
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
2.50%
5
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
45.00%32.50%22.50%
25.00%47.50%22.50%.00%
22.50%75.00%
27.50%60.00%7.50%5.00%
% Never % Frequently
% Sometimes % Always
thrombocytopenia from a sustained platelet count < 100 × 109/， and
Figure 1: Results obtained in the section of the questionnaire regarding diagnosis of ITP. Distribution of the percentages of responses.
study (participation rate 30.2%) and 39 fully completed the
questionnaire (response rate 97.5%). A total of 57.5% of
participants reported a professional experience between 5
and 20 years in the management of ITP (10% less than 5
years and 17.5%more than 20 years), and 60% had an annual
number of newly diagnosed patients between 5 and 15. The
number of specialists in their respective hospital services
varied between three and four in 30.7% of the cases, being
greater than four in 28.2%. Also, 94% of the respondents
reported freedom to prescribe any medication necessary for
the management of patients with ITP.
3.2. Diagnosis. In this section of the questionnaire, consensus
was reached in three of the four items (Figure 1). Experts
agreed on the need to indicate workup studies in the presence
of a sustained platelet count < 100 x 109/L in the absence
of any clear causative condition for the decreased platelet
count. Also, consensus was reached in favor of performing
bone marrow aspiration in elderly patients with suspicion of
ITP. We considered people older than 65 years old elderly or
fragile. By contrast, participants did not consider performing
bone marrow aspiration in all patients with suspicion of
ITP adequate. In addition, regarding the need for screening
Helicobacter pylori infection in case of suspicion or diagnosis
of ITP, 45% of respondents considered that screening should
be performed and 55% considered that screening should only
be performed in some cases or never. Details of the results
obtained in each section of the questionnaire are shown in
Table 1 of the Supplementary Material.
3.3. First-Line Treatment. In this section that included 11
items (Figure 2(a)), consensus was reached for 7 questions.
Participants coincided in starting treatment in asymptomatic
patients with a platelet count < 20 x 109/l, being indispensable
in patients with symptoms although at higher platelet counts.
Also, they agreed in favor of not exceeding 6-7 weeks of
treatment in patients treated with corticosteroids. There
was consensus against starting treatment in asymptomatic
patients with a platelet count > 20 x 109/L, maintaining the
chronic use of corticosteroids at doses of ≤ 5 mg, prescribing
immunoglobulins as the treatment of choice in the absence
of bleeding, and increasing the dose of treatment in the
presence of a decrease in platelet count during discontinu-
ation of corticosteroids. Finally, no consensus was reached
in starting treatment in a patient > 65 years of age without
comorbidities, regarding the statement that dexamethasone
implies some advantage over prednisone, resuming treatment
with corticosteroids within the first 6 months after relapse,
and in the use of corticosteroids in a patient with chronic ITP
that had never needed treatment before.
3.4. Second-Line Treatment. In this section that included 12
items (Figure 2(b)), consensuswas reached in 7 questions and
there was lack of consensus in 5. 97,5% of the participants
considered TPO-RA as the treatment of choice in second-line
in comparison with other therapeutic options. Participants
agreed to recommend bone marrow aspiration before start-
ing second-line treatment and prescribe thromboembolic
prophylaxis after splenectomy during a 2-4 weeks’ period
while maintaining safety platelet level. In case of treatment
failure with a TRA, they considered switching to another
TRA adequate. On the other hand, they agreed against
performing a bone marrow biopsy before the switch, as well
as prescribing antiplatelet agents’ therapy in patients with a
sustained platelet count > 500 x 109/L. They also stated that,
in patients treated with TRAs who had maintained a platelet
count > 100 x 109/L, it would be advisable to progressively
reduce the treatment doses until withdrawal. Regarding the
questions in which there was no consensus (Table 1 Sup-
plementary Material), 56% of participants considered using
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reshold: consensus in favor
(Always / Frequently > 66%)
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
Do you consider appropriate to start treatment in an asymptomatic 2.56%
7.50%
28.21%
60%
35.00%
43.59%
37.50%
57.50%
25.64%
2.50%
15.00% 47.50% 25.00% 12.50%
15.38% 48.72%
94.87%
35.90%
2.56% 2.56%
15.38% 53.85% 30.77%
56.41% 38.46% 5.13%
10.26% 53.85% 30.77% 5.13%
28.21%
43.59% 15.38%
56.41%
28.21%
15.38%
12.82%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
reshold: consensus against 
(Never / Sometimes > 66%)
% Never % Frequently
% Sometimes % Always
Do you consider appropriate to start treatment in an asymptomatic 
Do you consider appropriate to start treatment in a symptomatic 
Do you consider appropriate to start treatment in a patient aged
> 65 years without comorbidities?
Do you consider appropriate to state that dexamethasone involves 
any advantage for the patient over prednisone in the first-line 
treatment of ITP?
Do you consider appropriate to select immunoglobulins as a treatment 
of choice in a patient with ITP with absence of bleeding?
Do you consider appropriate not to exceed 6-7 weeks of treatment in
patients treated with corticosteroids?
Do you consider appropriate to maintain treatment with corticosteroids
at a dose of ≤ 5 mg chronically?
Do you consider appropriate to re-treat a patient with corticosteroids
within the first 6 months aer relapse?
If a decrease in platelet count during gradual reduction of corticosteroids 
is observed, do you consider it appropriate to increase the dose of 
treatment?
Do you consider appropriate to use steroids in a patient with chronic ITP
who had never needed treatment?
patient and with a platelet count < 20 × 109/，?
patient and with a platelet count > 20 × 109/，?
patient and with a platelet count > 20 × 109/，?
(a)
reshold: consensus in favor
(Always / Frequently > 66%)
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
Do you consider adequate to swi to second-line treatment in a patient
treated with corticosteroids presenting relapse within the first year aer
response?
Do you consider appropriate to perform a bone marrow biopsy before
starting second-line treatment?
23.08%
40.00%
38.46%
35.00%
33.33% 5.13%
20.00% 5.00%
Do you consider appropriate to indicate bone marrow aspiration before 
starting second-line treatment?
15.00% 17.50% 43.00% 25.00%
Do you consider appropriate to consider a splenectomy if, aer 12 
months of treatment, the platelet count has not increased up to safe
levels?
Do you consider appropriate to use thrombopoietin analogues in 
second-line treatment before splenectomy?
5.00%
45.00%
50.00% 45.00%
52.50% 2.50%
Do you consider appropriate to indicate thromboembolic prophylaxis 
during 2 to 4 weeks aer splenectomy, if safe platelet levels are 
maintained?
Do you consider appropriate to indicate platelet antiaggregants if there 
7.50% 7.50% 35.00%
50.00% 30.00%
50.00%
17.50% 2.50%
Do you consider appropriate to state that the platelet threshold to maintain 
5.00% 32.50% 42.50% 20.00%
Do you consider appropriate to check the minimum effective dose in 
patients treated with thrombopoietin analogues with a platelet count
Do you consider appropriate to use rituximab aer failure of treatment 
with thrombopoietin analogues?
7.69%
33.33%
56.41%
28.21% 30.77%
33.33%
7.69%
2.56%
Do you consider appropriate in patients treated with a thrombopoietin 
reduce the dose until withdrawal?
In case of treatment failure with a thrombopoietin analogue, do you 
consider it adequate to start a new line of treatment with another 
thrombopoietin analogue?
2.56%
7.69%
20.51%
69.23%
53.85% 23.08%
23.08%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
reshold: consensus against 
(Never / Sometimes > 66%)
is a sustained platelet count > 500 × 109/，?
< 50 × 109/，?
the minimum dose of thrombopoietin analogues is > 50 × 109/，?
% Never % Frequently
% Sometimes % Always
analogue with a sustained platelet count > 100 × 109/，, to gradually
(b)
Figure 2: Results obtained in the section of the questionnaire regarding first-line treatment (a) and second-line treatment (b) of ITP.
Distribution of the percentages of responses.
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rituximab in third line after treatment failure of TRA appro-
priate.
3.5. Persistent ITP andRefractory Patients. In this section that
included 16 items, consensus was obtained in 11 questions,
with a lack of consensus in the remaining 5. In relation
to patients with persistent ITP, it was considered adequate
that patients with symptoms and platelet count > 20 x 109/L
should be treated, and it is necessary to begin treatment
with TRA if they were either unresponsive to corticosteroids
or corticosteroid-dependent, whereas it was not considered
adequate to use rituximab. Also, it was not considered
adequate to maintain prolonged corticosteroids treatment
at doses of ≤ 5 mg, even in the presence of an acceptable
platelet count. In those items in which consensus against
the statement was obtained, the recommendation of not
using monotherapy with danazol or dapsone, or in combina-
tion with TPO-RA, in refractory patients to corticosteroids,
splenectomy, rituximab, and TRA agents should be noted.
Moreover, consensus against starting treatment in a patient
with persistent ITP, asymptomatic, and with a platelet count
> 20 x 109/l was reached, as well as in a patient with persistent
ITP and older than 65 years of age, without comorbidities,
and with a platelet count of 20-30 x 109/L. On the other hand,
54% of participants reported that abstaining from treatment
associated with antifibrinolytic agents may be considered in
refractory patients with a platelet count < 20 x 109/L without
bleeding symptoms, if the patient’s lifestyle allows for this
decision (Figure 3). Details of the percentages of response
for each question are shown in Table 1 of the Supplementary
Material.
3.6. Followup. In this section of 12 items, specialists reached
consensus in 6 questions and there was no consensus in
the remaining 6 (Figure 4). Mucosal or severe bleeding was
considered a basic criterion for admission to the hospital.
They also agreed on the need to educate patients in the
recognition of bleedingmanifestations.They did not consider
that a platelet count < 10 x 109/L or between 20 and 30 x 109/L,
in the absence of bleeding, was a criterion for hospitalization.
Participants discarded to make specific recommendations
regarding the frequency of visits based on the disease and
preferred to schedule consultations according to the individ-
ual characteristics of each patient (Table 1, Supplementary
Material).
3.7. Pregnancy. In the 12 items related to the management of
patients with ITP during pregnancy, consensus was reached
in 7 items. In the remaining 5 items, consensus was not
obtained. Participants agreed to establish aminimum platelet
count of 80 x 109/L to perform a vaginal delivery and epidural
anesthesia and did not consider it adequate to carry out a
cesarean section with a platelet count < 50 x 109/L or epidural
anesthesia in patients with a platelet count < 80 x 109/L.
In pregnant patients with platelet counts between 50 and
80 x 109/L, workup studies to exclude the diagnosis of ITP
were recommended, being indispensable in patients with a
platelet count < 50 x 109/L. Also, there was an agreement
regarding the importance of starting treatment in patients
without hemorrhagic diathesis and aminimumplatelet count
of 30 x 109/L even during the first trimester of pregnancy
(Figure 5(a)) (Table 1, Supplementary Material).
3.8. Emergencies, Surgery, and Safety. In this section of the
questionnaire that included 14 items, consensus was reached
in 10 items, whereas in the remaining 4, consensus was
not obtained (Figure 5(b)). Participants believed that platelet
transfusion was essential in cases of severe bleeding or life-
threatening hemorrhage, as well as the administration of
platelets with previous immunoglobulins and the use of
antifibrinolytic agents in hemorrhage. Participant also agreed
to establish aminimumplatelet count of 50 x 109/L to indicate
treatment with antiplatelet agents and anticoagulants and
between 30 and 50 x 109/L for surgical procedures of low
hemorrhagic risk. In untreated patients with ITP and platelet
count lower than that required for elective surgery, the use
of corticosteroids or immunoglobulins was recommended.
In addition, the use of TRA drugs was recommended in
untreated patients, who have been responsive to corticos-
teroids or immunoglobulins, with a platelet count lower than
that established for elective surgery (Table 1, Supplementary
Material).
3.9. Secondary Immune Thrombocytopenia. In this section
of 3 items, participants recommended to manage secondary
immune thrombocytopenia in the same way as ITP provided
that the underlying disease was controlled (Figure 6) (Table
1, Supplementary Material).
4. Discussion
The aim of the Delphi method is to obtain an opinion, level
of agreement, or consensus on a current topic or concern
from among a group of specialists or experts. This is an
iterative and anonymous process with controlled feedback
and analysis of the results widely used in health sciences
[21–23] Although the Delphi methodology has been applied
in various hematology studies [24–28], no previous studies
comprising a consensus of opinion have been published
on ITP using the Delphi technique. With respect to the
percentages of respondents having completed the rounds
of questions set, the data varies depending on the char-
acteristics of the study, including the number of experts,
survey distribution methods, number of rounds, face-to-
face meetings, etc. The participation rate in our study was
30.2%, but the percentage of participants having completed
the Delphi rounds was 97.5%, being in the upper band of
the range between 60% and 100% described in other similar
studies published in the literature [22–28].
Different scientific societies and expert groups have
developed guidelines and consensus documents with recom-
mendations for the diagnosis and treatment of adult patients
with ITP [10, 11, 29, 30]. However, agreement between rec-
ommendations and their application in real clinical practice
continues to be insufficient [20, 31]. In the study by Lozano
et al. [20] on the management of 101 adult patients with
6 Advances in Hematology
reshold: consensus in favor
(Always / Frequently > 66%)
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
Do you consider appropriate to start a line of treatment with 
to corticosteroids or who are corticoid-dependent?
2.50% 62.50% 35.00%
Do you consider appropriate to start a line of treatment with rituximab in 
patients with persistent ITP without response to corticosteroids or who are 
corticoid-dependent?
32.50% 62.50% 5.00%
Do you consider appropriate to start treatment in an asymptomatic 
2.50% 42.50% 42.50% 12.50%
Do you consider appropriate to start treatment in a patient with persistent
67.50% 25.00% 5.00% 2.50%
Do you consider appropriate to start treatment in a symptomatic patient 
7.50% 12.50% 32.50% 47.50%
Do you consider appropriate to start treatment in a patient with 
persistent ITP, aged > 65 years, without comorbidities and a 
25.00% 65.00% 10.00%
Do you consider appropriate to start treatment in a patient with 
persistent ITP, aged > 65 years, with comorbidities, and a platelet
Do you consider appropriate to maintain chronic treatment with 
corticosteroids at doses ≤ 5 mg in patients with persistent ITP, if the
platelet count with that treatment is acceptable?
12.50%
42.50%
45.00% 40.00%
25.00% 22.50%
2.50%
10.00%
Do you consider appropriate to indicate a therapeutic abstinence 
associated with antifibrinolytic agents in refractory patients (to steroids, 
immunoglobulins, splenectomy, and thrombopoietin analogues) with
lifestyle allows it?
In refractory patients to corticosteroids, splenectomy, rituximab and 
thrombopoietin analogues, do you consider appropriate to select 
non-steroidal immunosuppressants in monotherapy as the next 
treatment option?
In refractory patients to steroids, splenectomy, rituximab and 
thrombopoietin analogues, do you consider appropriate to select
non-steroidal immunosuppressants in combination with thrombopoietin 
analogues as the next treatment option?
5.13%
12.50%
41.03% 43.59%
55.00% 40.00%
47.50% 35.00%
10.26%
5.00%
5.00%
In refractory patients to steroids, splenectomy, rituximab and 
thrombopoietin analogues, do you consider appropriate to select 
monotherapy with danazol as the next treatment option?
7.50% 72.50% 20.00%
In refractory patients to steroids, splenectomy, rituximab and 
thrombopoietin analogues, do you consider appropriate to select 
monotherapy with dapsone as the next treatment option?
22.50% 70.00% 7.50%
In refractory patients to steroids, splenectomy, rituximab and 
thrombopoietin analogues, do you consider appropriate to select 
corticosteroids combined with thrombopoietin analogues as the next 
treatment option?
15.00% 52.50% 30.00% 2.50%
In refractory patients to steroids, splenectomy, rituximab and 
thrombopoietin analogues, do you consider appropriate to select danazol 
combined with thrombopoietin analogues as the next treatment option?
25.00% 70.00% 5.00%
In refractory patients to steroids, splenectomy, rituximab and 
thrombopoietin analogues, do you consider appropriate to select 
dapsone combined with thrombopoietin analogues as the next 
treatment option?
47.50% 50.00% 2.50%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
reshold: consensus against 
(Never / Sometimes > 66%)
% Never % Frequently
% Sometimes % Always
thrombopoietin analogues in patients with persistent ITP without response
patient with persistent ITP and a platelet count < 20 × 109/，?
ITP, asymptomatic and with a platelet count > 20 × 109/，?
with persistent ITP and a platelet count > 20 × 109/，?
platelet count of 20-30 × 109/，?
count of 20-30 × 109/，?
a platelet count < 20 × 109/， and without bleeding symptoms if his/her
Figure 3: Results obtained in the section of the questionnaire regarding persistent ITP and refractorypatients. Distribution of the percentages
of responses.
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reshold: consensus in favor
(Always / Frequently > 66%)
100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
Do you consider mucosal bleeding or severe bleeding as a basic 
criterion for hospital admission in an adult patient with ITP?
2.57% 33.33% 64.10%
hemorrhage as a basic criterion for hospital admission in an
adult patient with ITP?
hemorrhage as a basic criterion for hospital admission in an adult 
patient with ITP?
17.50% 45.00%
82.50%
25.00% 12.50%
17.50%
Do you consider appropriate to evaluate every 1 or 2 weeks a patient
with ITP under active treatment with thrombopoietin analogues and a
stable platelet count?
Do you consider appropriate to evaluate monthly a patient with ITP under 
active treatment of thrombopoietin analogues and a stable platelet count?
17.95%
82.50%
33.33% 41.03%
7.50% 7.50% 2.50%
7.69%
Do you consider appropriate to evaluate every two months a
patient with ITP under active treatment with thrombopoietin 
analogues and a stable platelet count?
7.69% 35.90% 43.59% 12.82%
Do you consider appropriate to evaluate with a frequency higher than 2
months a patient with ITP under active treatment with thrombopoietin
analogues and a stable platelet count?
Do you consider appropriate to evaluate every 1 or 2 weeks a 
patient with ITP under active treatment (other than TPOa) and a
stable platelet count?
Do you consider it appropriate to evaluate every month a patient with ITP 
under active treatment (other than a TPOa) and a stable platelet count?
10.26% 53.85%
71.79%
37.50% 40.00%
25.64%
17.95%
20.00%
10.26%
10.26%
2.50%
Do you consider it appropriate to evaluate every 2 months a 
patient with ITP under active treatment (other than TPOa) and a
stable platelet count?
17.50% 40.00% 40.00% 2.50%
Do you consider appropriate to evaluate more frequently than every
2 months a patient with ITP under active treatment (other than TPOa)
and a stable platelet count?
Do you consider appropriate to educate patients in the recognition of
the hemorrhagic symptoms for requesting an appointment for 
medical consultation?
10.00%
2.50% 7.50%
52.50%
90.00%
30.00% 7.50%
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
reshold: consensus against 
(Never / Sometimes > 66%)
Do you consider a platelet count between 20 and 30 × 109/， without
% Never % Frequently
% Sometimes % Always
Do you consider a platelet count < 10 × 109/， without
Figure 4: Results obtained in the section of the questionnaire regarding the follow-up of patients with ITP. Distribution of the percentages
of responses.
ITP, data collected from the medical records were compared
with guidelines recommendations, and important inconsis-
tencies in diagnosis and treatment were found. Regarding
diagnosis, a cytological examination of the peripheral blood
was never performed in 22.8% of the patients despite being
recommended by all guidelines, whereas in more than one
half of the patients (50.5%), a study of the bone marrow
was carried out in the initial diagnosis even though this
examination is not recommended routinely by the guidelines.
In the present study, areas in which consensus was reached
were generally in agreement with clinical practice guidelines,
but there were some aspects in the clinical management of
ITP that were not present in the guidelines and for which
unified criteria are needed. Thus, participants agreed on the
need that treatment with corticosteroids should not exceed
6-7 weeks, whereas in routine clinical practice, as published
by Lozano et al. [20], the mean duration of treatment with
corticosteroids was more than 70 days. In relation to the
use of corticosteroids, it is interesting to note that whereas
the study of Lozano et al. [20] revealed that 37.5% of
patients received corticosteroids as second-line treatment,
in the present consensus it was not considered appropriate
to maintain chronic corticosteroid treatment at doses of ≤
5 mg in patients with persistent ITP, even in the presence
of an acceptable platelet count. In our study, participants
denied the need of performing systematically bone marrow
aspiration in patients with suspicion of ITP except in elderly
patients. There is no study to recommend this practice in
elderly patients but the risk of myelodiplastic syndrome in
this group of patients is present.
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Do you consider appropriate to perform a vaginal delivery with a platelet
Do you consider it appropriate to perform a vaginal delivery with a platelet 
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or immunoglobulins, with a platelet count lower than that recommended
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surgery with low bleeding risk (e.g. single tooth extraction, localized
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Figure 5: Results obtained in the section of the questionnaire regarding the management of patients with ITP during pregnancy (a) and in
aspects related to emergencies, surgery, and safety (b). Distribution of the percentages of responses.
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reshold: consensus in favor 
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Do you consider appropriate to manage secondary immune 
thrombocytopenia in the same way as ITP, if the underlying 
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Figure 6: Results obtained in the section of the questionnaire regarding secondary immune thrombocytopenia. Distribution of the
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Other interesting aspects inwhich consensuswas reached
refer to asymptomatic patients in whom starting treatment
was established at a threshold platelet count of < 20 x 109/L.
In Spain, our real practice considers treatment in patients
with less than 20,000 platelets, and we reflect that way
of treatment in our national consensus of ITP treatment
although we do not have our own publication to justify it.
There are guidelines that indicate the possibility of treating
the patient in the absence of relevant bleeding if the platelet
count is between 20 and 30 x 109/L [10, 32], while others
do not recommend it [30, 33, 34]. Bleeding events was the
major criterion for the initiation of treatment according
to the expert panel. Age and comorbidity are also crite-
ria that may be considered in decision making, although
the toxicities of classical treatments in older patients are
higher and have a greater risk for bleeding. In patients with
ITP who do not respond to corticosteroids or are steroid-
dependent, most participants would administer a TRA
agent.
There are other clinically relevant aspects in the current
clinical practice scenario for which consensus was obtained
and that are not included in the guidelines, such as the con-
venience of switching to a different TRA drug in the event of
previous TRA failure and the possibility of using these agents
in the context of the patient’s preparation for surgery, in
secondary ITP, or in combination with immunosuppressant
drugs in multirefractory patients. Regarding combination
therapy, there are case reports and a retrospective series of
Mahévas et al. [35] with a favorable response in 70% of
patients. On the other hand, the recommendation suggested
in different studies seems also very interesting [33, 34],
although predictors of sustained response in this setting
remain unclear. Recently, some clinical practice experience
has been published showing that patients treated with such
agonists who maintain a platelet count higher than 100 x
109/L for 3 months have a greater likelihood of success after
discontinuation of treatment [36, 37].
Treatment of refractory ITP is a clinical challenge and
frequently the results obtained are poor. In this study, no
consensus was reached regarding the management of refrac-
tory patients to TRA, splenectomy, and rituximab [38].
Results of the present study should be interpreted con-
sidering that responses to the questionnaire reflect the
specialists’ views of what they would do in different sce-
narios posed by each question, and not necessarily what
they do in real clinical practice. However, the Delphi
method allowed exploring systematically the management of
adult patients with ITP based on the qualified opinion of
physicians routinely treating these patients. Themanagement
of patients with ITP is rapidly evolving, and over the last
15 years, several novel treatments have improved practice,
with many steroid-sparing agents and a significant reduc-
tion in the splenectomy rate. Although this has improved
clinical care, many therapeutic challenges remain. There is
no diagnostic test or biomarkers to direct treatment and
there are few comparative studies to help management deci-
sions.
5. Conclusions
This Delphi survey study conducted in a sample of hematol-
ogists members of the Spanish Immune Thrombocytopenia
Group (GEPTI) of the Spanish Society of Hematology and
Hemotherapy may offer a clear framework of the real man-
agement of adult patients with ITP in clinical practice.
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